Insulet awarded $452M in EOFlow patent fight by Elise Reuter for MedTechDive.com, 5 December 2024.
Insulet sued EOFlow and three former executives who joined the South Korea-based patch-pump maker, claiming the company “launched a plan to brazenly copy Insulet’s Omnipod System.” In October 2023, the Massachusetts district court issued a preliminary injunction against EOFlow. Following that decision, Medtronic called off plans to buy EOFlow for about $738 million.
The Massachusetts jury found this week that EOFlow and CEO Jesse Kim, as well as two of three former Insulet employees who were named as defendants in the lawsuit, misappropriated Insulet’s trade secrets. Insulet CEO Jim Hollingshead said the company is “extremely pleased with the jury’s verdict.”
Read more: Insulet awarded $452M in EOFlow patent fight
New Study Teases Out Chocolate and Diabetes Connection by Sophie Putka for MedPageToday.com, 4 December 2024.
Eating more dark chocolate was associated with a lower risk of type 2 diabetes. Among participants across three studies of healthcare workers, those who consumed ≥5 servings per week of dark chocolate had a 21% lower risk of type 2 diabetes compared with those who never or rarely consumed dark chocolate, reported Qi Sun, MD, ScD, of the Harvard T.H. Chan School of Public Health in Boston, and colleagues in The BMJ. There was no significant association between consumption of milk chocolate and type 2 diabetes, but intake of milk chocolate was positively associated with weight gain, while this was not the case for dark chocolate.
“We were surprised to see a stark contrast between dark and milk chocolate,” co-author Binkai Liu, MS, also of Harvard T.H. Chan School of Public Health, told MedPage Today. “While dark chocolate was associated with a lower risk of type 2 diabetes, milk chocolate showed no such benefit and was even associated with weight gain. This difference underscores the importance of chocolate type and its nutrient composition.”
Chocolate is high in polyphenols, including flavanols (part of the larger flavonoid group), and previous studies have shown an association between higher dietary flavonoid consumption and decreased type 2 diabetes risk. Though flavonoids may confer antioxidant, anti-inflammatory, and vasodilatory benefits, the relationship between chocolate consumption and diabetes remains “controversial,” the authors wrote, due to observational studies with inconsistent findings, and a lack of inquiry into health effects by chocolate subtype.
Read more: New Study Teases Out Chocolate and Diabetes Connection
DKA Risk at Different SGLT2 Inhibitor Doses in T1DM Treatment by Ying Liu et all for Frontiersin.org, 3 December 2024.
The following is a summary of “Risk of diabetic ketoacidosis caused by sodium-glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized controlled trials,” published in the December 2024 issue of Endocrinology by Liu et al.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors benefit individuals with type 1 diabetes mellitus (T1DM), but the risk of diabetic ketoacidosis (DKA) limits their widespread use. Researchers conducted a retrospective study to evaluate the risk of DKA in people with T1DM treated with different doses of SGLT2 inhibitors.
They concluded that individuals with T1DM treated with dapagliflozin, empagliflozin, and sogliflozin have an increased risk of DKA, while canagliflozin 300 mg demonstrated the lowest DKA risk.
Read more:
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes was announced by Boehringer-Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision), 12 November 2024.
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term collaboration as Boehringer becomes the first pharmaceutical company to join the MTM Vision Consortium. Housed at the University of Michigan, the MTM Vision Consortium aims to unite innovators in the pre-competitive space from universities, foundations, as well as pharmaceutical and biotech companies. MTM Vision leads this international collaboration, motivated by the urgency of millions of people worldwide who have lost or are at risk of losing their eyesight as a consequence of diabetes.
The Consortium members share several goals: address the need for novel means to better diagnose and stage DRD; validate promising clinical trial endpoints and biomarkers; and accelerate the development of breakthrough therapies. These efforts will enable treatment earlier in disease before vision loss occurs, and contribute to the creation of new regulatory pathways for drug approval.
“We are excited to join forces with MTM Vision in leading a new era of vision preservation and protection for people living with diabetes. This collaboration will help us enhance our understanding of the progression of diabetic retinopathy and the role of retinal non-perfusion, supporting the development of our portfolio in diabetic retinal diseases,” said Dr. Ulrike Graefe-Mody, Global Head of Retinal Health at Boehringer Ingelheim. “It also gives us access to a unique biospecimen bank, accelerating our research and biomarker identification. In return, we are openly sharing our current efforts for evidence generation to further understand DRD and support MTM Vision’s work. Together, we are setting a course to fundamentally change our understanding of vision loss from diabetes and how it is treated.”
